The initial impetus to create a work combining aspects of cel- lular immunology with their clinical applications grew from the ed- itors' discussions of the area's needs with many of the leaders in the field over a period of time. From the nucleus of ideas that emerged, we have here attempted to create a unified and inte- grated coverage of the rapidly growing field of cellular immunology research and to trace out-from what seems at times a genuine plethora of important new findings-the many and often impor- tant clinical implications. Because of this approach, the chapters of Clinical Cellular Im- munology attempt to be more than critical reviews of research and clinical data, going beyond analysis to synthesize working hypotheses about the functional meaning of cellular immunological phenomena and their likely clinical significance. To accomplish this undertaking, the text begins first with a consid- eration of the molecular aspects of antigen recognition (Luderer and Harvey) and of the ensuing regulatory program initiation (Fathman).Then, the functional subsets oflymphocytes as they in- teract to produce and control the developing immune response are explored in detail (Sigel et a1.), followed by a unique analytical dis- section of the action of immunosuppressive agents on the sundry inductive and regulatory immunologic pathways (Sigel et al.). A majority of the data and conclusions drawn by the authors in the previous chapters arise from work on murine systems, al- though wherever appropriate, human data has been introduced.

The early, organ-specific diagnosis of malignancy continues to be a major unmet medical need. Clearly the ability to establish an early diagnosis of cancer is dependent upon an intimate knowledge of the cancer's biology, which if understood at the molecular level should identify key diagnostic and therapeutic manipulation points. Advances in recombinant gene technology have provided significant understanding of the mechanisms of action of oncogenic viruses, as well as of cancer-associated genomic sequences (onco­ genes). This text will explore the known molecular genetic, biolog­ ical, and clinical knowledge of selected human neoplasms that demonstrate association with suspected oncogenic virus and those cytogenetic alterations that either cause or are caused by oncogene activation. The text first reviews the cytogenetics of human cancers link­ ing classical cytogenetics and molecular genetics. Avery A. Sand­ berg (Roswell Park Memorial Institute, Buffalo, New York) reviews the leukemias and lymphomas, followed by S. Pathak (M. D. Anderson Hospital and Tumor Institute, Houston, Texas), who reviews solid tumors. Functional consideration of oncogenes is highlighted by Keith C. Robbins and Stuart A. Aaronson (NO, Bethesda, Maryland) through their description of the v-sis locus sis and its gene product p.28 ; a protein that closely resembles human platelet-derived growth factor (PDGF).

The early, organ-specific diagnosis of malignancy continues to be a major unmet medical need. Clearly the ability to establish an early diagnosis of cancer is dependent upon an intimate knowledge of the cancer''s biology, which if understood at the molecular level should identify key diagnostic and therapeutic manipulation points. Advances in recombinant gene technology have provided significant understanding of the mechanisms of action of oncogenic viruses, as well as of cancer-associated genomic sequences (onco­ genes). This text will explore the known molecular genetic, biolog­ ical, and clinical knowledge of selected human neoplasms that demonstrate association with suspected oncogenic virus and those cytogenetic alterations that either cause or are caused by oncogene activation. The text first reviews the cytogenetics of human cancers link­ ing classical cytogenetics and molecular genetics. Avery A. Sand­ berg (Roswell Park Memorial Institute, Buffalo, New York) reviews the leukemias and lymphomas, followed by S. Pathak (M. D. Anderson Hospital and Tumor Institute, Houston, Texas), who reviews solid tumors. Functional consideration of oncogenes is highlighted by Keith C. Robbins and Stuart A. Aaronson (NO, Bethesda, Maryland) through their description of the v-sis locus sis and its gene product p.28 ; a protein that closely resembles human platelet-derived growth factor (PDGF).

The initial impetus to create a work combining aspects of cel- lular immunology with their clinical applications grew from the ed- itors' discussions of the area's needs with many of the leaders in the field over a period of time. From the nucleus of ideas that emerged, we have here attempted to create a unified and inte- grated coverage of the rapidly growing field of cellular immunology research and to trace out-from what seems at times a genuine plethora of important new findings-the many and often impor- tant clinical implications. Because of this approach, the chapters of Clinical Cellular Im- munology attempt to be more than critical reviews of research and clinical data, going beyond analysis to synthesize working hypotheses about the functional meaning of cellular immunological phenomena and their likely clinical significance. To accomplish this undertaking, the text begins first with a consid- eration of the molecular aspects of antigen recognition (Luderer and Harvey) and of the ensuing regulatory program initiation (Fathman).Then, the functional subsets oflymphocytes as they in- teract to produce and control the developing immune response are explored in detail (Sigel et a1.), followed by a unique analytical dis- section of the action of immunosuppressive agents on the sundry inductive and regulatory immunologic pathways (Sigel et al.). A majority of the data and conclusions drawn by the authors in the previous chapters arise from work on murine systems, al- though wherever appropriate, human data has been introduced.

The initial impetus to create a work combining aspects of cel- lular immunology with their clinical applications grew from the ed- itors' discussions of the area's needs with many of the leaders in the field over a period of time. From the nucleus of ideas that emerged, we have here attempted to create a unified and inte- grated coverage of the rapidly growing field of cellular immunology research and to trace out-from what seems at times a genuine plethora of important new findings-the many and often impor- tant clinical implications. Because of this approach, the chapters of Clinical Cellular Im- munology attempt to be more than critical reviews of research and clinical data, going beyond analysis to synthesize working hypotheses about the functional meaning of cellular immunological phenomena and their likely clinical significance. To accomplish this undertaking, the text begins first with a consid- eration of the molecular aspects of antigen recognition (Luderer and Harvey) and of the ensuing regulatory program initiation (Fathman).Then, the functional subsets oflymphocytes as they in- teract to produce and control the developing immune response are explored in detail (Sigel et a1.), followed by a unique analytical dis- section of the action of immunosuppressive agents on the sundry inductive and regulatory immunologic pathways (Sigel et al.). A majority of the data and conclusions drawn by the authors in the previous chapters arise from work on murine systems, al- though wherever appropriate, human data has been introduced.

The early, organ-specific diagnosis of malignancy continues to be a major unmet medical need. Clearly the ability to establish an early diagnosis of cancer is dependent upon an intimate knowledge of the cancer's biology, which if understood at the molecular level should identify key diagnostic and therapeutic manipulation points. Advances in recombinant gene technology have provided significant understanding of the mechanisms of action of oncogenic viruses, as well as of cancer-associated genomic sequences (onco­ genes). This text will explore the known molecular genetic, biolog­ ical, and clinical knowledge of selected human neoplasms that demonstrate association with suspected oncogenic virus and those cytogenetic alterations that either cause or are caused by oncogene activation. The text first reviews the cytogenetics of human cancers link­ ing classical cytogenetics and molecular genetics. Avery A. Sand­ berg (Roswell Park Memorial Institute, Buffalo, New York) reviews the leukemias and lymphomas, followed by S. Pathak (M. D. Anderson Hospital and Tumor Institute, Houston, Texas), who reviews solid tumors. Functional consideration of oncogenes is highlighted by Keith C. Robbins and Stuart A. Aaronson (NO, Bethesda, Maryland) through their description of the v-sis locus sis and its gene product p.28 ; a protein that closely resembles human platelet-derived growth factor (PDGF).

The early, organ-specific diagnosis of malignancy continues to be a major unmet medical need. Clearly the ability to establish an early diagnosis of cancer is dependent upon an intimate knowledge of the cancer''s biology, which if understood at the molecular level should identify key diagnostic and therapeutic manipulation points. Advances in recombinant gene technology have provided significant understanding of the mechanisms of action of oncogenic viruses, as well as of cancer-associated genomic sequences (onco­ genes). This text will explore the known molecular genetic, biolog­ ical, and clinical knowledge of selected human neoplasms that demonstrate association with suspected oncogenic virus and those cytogenetic alterations that either cause or are caused by oncogene activation. The text first reviews the cytogenetics of human cancers link­ ing classical cytogenetics and molecular genetics. Avery A. Sand­ berg (Roswell Park Memorial Institute, Buffalo, New York) reviews the leukemias and lymphomas, followed by S. Pathak (M. D. Anderson Hospital and Tumor Institute, Houston, Texas), who reviews solid tumors. Functional consideration of oncogenes is highlighted by Keith C. Robbins and Stuart A. Aaronson (NO, Bethesda, Maryland) through their description of the v-sis locus sis and its gene product p.28 ; a protein that closely resembles human platelet-derived growth factor (PDGF).

The initial impetus to create a work combining aspects of cel- lular immunology with their clinical applications grew from the ed- itors' discussions of the area's needs with many of the leaders in the field over a period of time. From the nucleus of ideas that emerged, we have here attempted to create a unified and inte- grated coverage of the rapidly growing field of cellular immunology research and to trace out-from what seems at times a genuine plethora of important new findings-the many and often impor- tant clinical implications. Because of this approach, the chapters of Clinical Cellular Im- munology attempt to be more than critical reviews of research and clinical data, going beyond analysis to synthesize working hypotheses about the functional meaning of cellular immunological phenomena and their likely clinical significance. To accomplish this undertaking, the text begins first with a consid- eration of the molecular aspects of antigen recognition (Luderer and Harvey) and of the ensuing regulatory program initiation (Fathman).Then, the functional subsets oflymphocytes as they in- teract to produce and control the developing immune response are explored in detail (Sigel et a1.), followed by a unique analytical dis- section of the action of immunosuppressive agents on the sundry inductive and regulatory immunologic pathways (Sigel et al.). A majority of the data and conclusions drawn by the authors in the previous chapters arise from work on murine systems, al- though wherever appropriate, human data has been introduced.